Key result
Cytomegalovirus immunoglobulin prophylaxis was associated with a decreased risk of death (HR 0.79, p<0.001) and improved 7-year recipient survival (69% vs 64%) compared to no prophylaxis.
Why the study?
Does CMV prophylaxis (CMVIG or antivirals) improve long-term recipient and graft survival in heart transplant recipients?
Population
28,862 primary, single-organ heart transplant recipients, ≤80 years old, transplanted between January 1995…
Comparison
Cytomegalovirus immunoglobulin with or without… vs No prophylaxis (n=14,661).
Design
Cohort
Follow-up
7 years
Authors
Loading...
May support CMVIG evaluation post-heart transplant; hypothesis-generating pending randomized confirmation of survival benefit.
Cohort (n=28,862)
Yes
Does CMV prophylaxis (CMVIG or antivirals) improve long-term recipient and graft survival in heart transplant recipients?
Hazard Ratio: 0.79
Absolute Event Rate: 69% vs 64%
p-value: p=<0.001
CMV prophylaxis with either CMVIG or antivirals alone at hospital discharge is associated with significantly improved long-term recipient and graft survival following heart transplantation.
Snydman et al. (2011) conducted a cohort in Heart transplantation (n=28,862). Cytomegalovirus immunoglobulin (CMVIG) with or without antivirals vs. No prophylaxis was evaluated on Recipient survival (death) (HR 0.79, p=<0.001). Cytomegalovirus immunoglobulin prophylaxis was associated with a decreased risk of death (HR 0.79, p<0.001) and improved 7-year recipient survival (69% vs 64%) compared to no prophylaxis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: